IMMUNOSUPPRESSION-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN RHEUMATIC PATIENTS

被引：43

作者：

KAMEL, OW

VANDERIJN, M

HANASONO, MM

WARNKE, RA

机构：

[1] Department of Pathology, Stanford University Medical Center, Stanford, CA

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 16卷 / 5-6期

关键词：

LYMPHOMA; LYMPHOPROLIFERATIVE DISORDER; RHEUMATOID ARTHRITIS; DERMATOMYOSITIS; SJOGRENS SYNDROME; EPSTEIN-BARR VIRUS;

D O I：

10.3109/10428199509054421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The association between rheumatic disease and the occurrence of hematolymphoid neoplasms has been a subject of investigation for many years. Recently, we and others have reported the development in rheumatic patients of lymphoproliferative disorders that are similar to those occurring in patients with known immunocompromised states. The lymphoid neoplasms that develop in patients with immunosuppression are characterized by several features including the presence of EBV genome in the neoplastic cells. The fact that lymphomas with features of those occurring in immunosuppressed patients can occur in patients with rheumatic disease suggests that immune system impairment secondary to the rheumatic disease, the treatment given for the rheumatic disease, or to a combination of these factors, might play a role in the development of lymphoma in these patients. This review will first describe the characteristics of lymphoproliferative disorders that occur in patients with known immunocompromised states. It will then review general aspects of lymphomas in rheumatic patients with a focus on more recent reports that have described the development of immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Studies that investigate the relative contribution of the rheumatic disease versus therapy for rheumatic disease in the development of lymphoma in this patient group are still needed.

引用

页码：363 / 368

页数：6

共 35 条

[1]

Nalesnik M.A., Makowka L., Starzl T.E., The diagnosis and treatment of posttransplant lymphoproliferative disorders, Curr. Probl. Surg., 25, 6, pp. 367-472, (1988)

[2]

Nalesnik M.A., Jaffe R., Starzl T.E., Et al., The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression, Am. J. Pathol, 133, 1, pp. 173-192, (1988)

[3]

Knowles D.M., Chamulak G.A., Subar M., Et al., Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS), Ann. Intern. Med., 108, pp. 744-753, (1988)

[4]

Biemer J.J., Malignant Lymphomas Associated with Immunodeficiency States, Annals Clin. Lab. Sci., 120, 3, pp. 175-191, (1990)

[5]

Starzl T.E., Nalesnik M.A., Porter K.A., Et al., Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, Lancet, 1, 8377, pp. 583-587, (1986)

[6]

Staal S.P., Ambinder R., Beschomer W.E., Et al., A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease, Am. J. Clin. Pathol., 91, 1, pp. 1-5, (1989)

[7]

Cleary M.L., Nalesnik M.A., Shearer W.T., Sklar J., Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus, Blood, 72, 1, pp. 349-352, (1988)

[8]

Young L., Alfieri C., Hennessy K., Et al., Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease, N. Engl. J. Med., 321, 16, pp. 1080-1085, (1989)

[9]

Purtillo D.T., Strobach R.S., Okano M., Davis J.R., Epstein-Barr virus-associated lymphoproliferative disorders, Lab. Invest., 67, pp. 5-23, (1992)

[10]

Filipovich A.H., Mathus A., Kamat D., Shapiro R.S., Primary immunodeficiencies: genetic risk factors for lymphoma, Cancer Res., 52, pp. 5465s-5467s

← 1 2 3 4 →